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Summary
Patients with locally advanced cancer or distant metastasis frequently receive prolonged treatment with chemotherapy and/or fractionated radiotherapy (RT). Despite the initial clinical response, treatment resistance frequently develops and cure in these patients is uncommon.
Developments in radiotherapy technology allow for the use of high dose (or ablative) RT to target local tumors, with limited damage to the surrounding normal tissue. We report that reduction of tumor burden following ablative RT depends largely on T cell responses. Ablative
RT dramatically increases T cell priming in draining lymphoid tissues, leading to reduction/eradication of the primary tumor or distant metastasis in a CD8 + T cell dependent
fashion. We further demonstrate that ablative RT-initiated immune responses and tumor reduction are abrogated by conventional fractionated RT or adjuvant chemotherapy, but greatly amplified by local immunotherapy. Our study challenges the rationale for current radio/chemotherapy strategies and highlights the importance of immune activation in preventing tumor relapse. Our findings emphasize the need for new strategies that not only reduce tumor burden but also enhance the role of anti-tumor immunity.
Introduction
The rationale for radiotherapy (RT) is based on inducing lethal DNA damage to tumor cells or tumor associated stroma. Cancer patients often receive fractionated RT at low doses (1.5-3 Gy) that are administered daily over weeks, frequently in combination with chemotherapy. RT has traditionally been viewed as immunosuppressive 1 , but studies published in recent years have suggested that the effects of RT on the immune system are complex. Lymphocyte radiosensitivity is well established, but whether varying doses or delivery methods can differentially target naïve, effector or regulatory T cell populations and/or alternative regulatory molecules, is still unclear [2] [3] [4] . While studies have investigated the potential immunomodulatory effects of localized RT on tumors, there have been conflicting reports as to whether these responses promote or interfere with tumor reduction [5] [6] [7] [8] .
A recent study showed that radiation can trigger signals that stimulate toll-like receptor 4 on dendritic cells (DC) 9 , suggesting another dimension of immune modulation by RT. Other studies reported a direct effect of radiation on tumors by either modifying the phenotype of tumor cells to render them more susceptible to vaccine-mediated T-cell killing 10 , or altering the tumor microenvironment to promote greater infiltration of immune effector cells [11] [12] [13] . A large tumor burden often creates severe suppression that prevents effective immune intervention. It has been proposed that local RT can induce a sufficient reduction in tumor burden to allow for therapeutic intervention by immunotherapy, such as vaccination or blockade of inhibitory molecules on immune cells 4, 10, 14 . Whether RT can also generate significant cytotoxic T lymphocytes (CTL) to kill metastasis has not been well documented.
Advances in radiotherapy technology allow for the use of ablative RT to be delivered very precisely to small tumors. For example, stereotactic body RT (SBRT) takes advantage of the technological advancements in image guidance and radiation dose delivery in order to direct
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From ablative doses to tumors with acceptable toxicity. Phase I/II trials have provided evidence that the potent doses delivered with SBRT may provide results that rival surgery for some localized primary tumors and has efficacy in the oligometastatic setting 15, 16 . The initial clinical reports indicate that the use of ablative RT is associated with better survival than conventional fractionated treatment, but the mechanisms remain unclear [15] [16] [17] [18] . Using an animal model, we unexpectedly observed that ablative RT (15-25 Gy x1) alone, generates strong enough CD8 + T cell dependent immunity to lead to tumor reduction, reduced relapse of primary tumor, and even eradication of metastasis in some settings. The clinical implication of this study is that some current strategies employing fractionated radiotherapy or chemotherapy may limit RT-mediated immunity and increase relapse over time. Indeed, we also demonstrate that ablative RTmediated immunity is erased by current conventional chemotherapy and prolonged fractionated radiotherapy, resulting in early relapse due to inadvertent suppression of protective immune responses. On the other hand, ablative RT followed by proper immunotherapy can synergistically overcome the tumor barriers and generate more cytotoxic T cells that circulate systemically to eradicate micro-metastasis. Therefore, we should revisit our current strategies and develop new approaches that can reduce tumor burden while boosting protective immunity.
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Materials and methods:
Mice, cell line, and reagents C57BL/6, Nude, B6/Rag, OTI, and Balb/c mice were purchased from Jackson Laboratory at 6-7 weeks old. 2C TCR-transgenic mice were provided by Jianzhu Chen, MIT, Cambridge, MA, and maintained in the specific pathogen free (SPF) facility at the University of Chicago. For all experiments, mice were between the ages of 6-16 weeks of age, bred under SPF conditions and used in accordance to the animal experimental guidelines set by and with the approval of the Institute of Animal Care and Use Committee (IACUC). 4T1 is a 6-thioguanine-resistant cell line derived from spontaneous mammary carcinoma 19 . B16 lines were obtained by ATCC and maintained Fu and Weichselbaum. B16-SIY melanoma cells and anti-2C TCR (1B2) antibody were obtained from Tom Gajewski (The University of Chicago). B16-CCR7 melanoma cell was generously provided by Sam T. Hwang (National Cancer Institute) 20 .
The human lung tumor cell line A549 was purchased from ATCC. All other antibodies for FACS were purchased from BD Biosciences. The generation of ad-LIGHT was described previously 21 .
Harvesting of mouse lymphoid DC For DC harvest for FACS, draining lymph nodes (DLN) and spleen (SP) were digested with 1.5 mg/ml collagenase and 100 µg/ml DNase for 20 min at 37°C and then gently pipetted in the presence of 0.01 M EDTA for 1 min. Single-cell suspensions were stained and analyzed by flow cytometry on a FACSCanto (BD Biosciences). 21, 22 . Cells were isolated from the inguinal LNs (DLNs), SP, or tumors at the time indicated. CFSE dilution was evaluated as described before 21, 22 . For personal use only. on October 3, 2017. by guest www.bloodjournal.org From and B16-CCR7 tumors as previously described 19 . Briefly, lungs for 4T1 tumor or DLN for B16-CCR7 were collected, chopped and dissociated in DMEM supplemented with 10% FCS containing 1.5 mg/ml collagenase type D (Sigma-Aldrich) for 20 min in 37°C shaking incubator.
TCR tetramer and FACS staining
Single cell suspensions were plated at various dilutions in media supplemented with 10% FCS and selection drug. 4T1 is resistant to 6-thioguanine (60 mM) and B16-CCR7 is resistant to G418 (0.7 mg/ml). Individual colonies representing micrometastases were counted after 5-10 days 19 .
Statistical analysis Statistics were done using an unpaired student two-tailed t test. Error bars represent standard deviations. For survival curves statistics were done using the log rank
Results

Ablative RT induces strong T cell responses leading to tumor rejection
B16 melanoma is well established to be a highly aggressive, rapidly growing, poorly immunogenic, radio-resistant tumor and also known to resist various treatments including immunotherapies 14, 23 . Intriguingly, we observed that after ablative RT (20 Gy x1) B16 tumors show significant regression in wt mice (Fig. 1A) and an increase of infiltrating T cells to the tumor microenvironment and the lymphoid tissues 1-2 weeks after treatment (data not shown).
This raised the possibility that the sensitivity to RT observed in vivo was T cell-mediated.
Therefore, nude mice (T cell deficient) were used to determine the role of T cells in RT-mediated B16 tumor reduction. Impressively, the tumor remained radio-resistant to ablative RT in the absence of T cells (Fig. 1A) . Similar results were observed in B and T cell deficient B6/Rag Within 48 hours post local RT, there was an increased percentage of MHC class II on mDCs, but not plasmacytoid DC (pDC) compared to no RT (Fig 2C and data not shown) . Together, ablative RT on the tumor can activate and mature DCs to subsequently facilitate better T cell priming.
Radiation-initiated immunity and anti-tumor effects can be suppressed by either chemotherapy or fractionated radiation
As chemotherapy is often combined with RT in clinical practice, our results raised concern about the potential immunosuppressive effects of prolonged chemotherapy on RTmediated immunity. Indeed, chemotherapy given as adjuvant after localized radiotherapy significantly hindered tumor regression and promoted melanoma outgrowth (Fig. 3A) . One of the goals of adjuvant chemotherapy after surgery and radiation is to reduce subclinical metastasis.
In the 4T1 breast tumor model, the influence of RT-mediated tumor regression was less pronounced in regards to the primary tumor (Fig. 3B ) yet impressively, lung metastases with ablative RT were completely eliminated (Fig. 3C) . The prolonged effect of ablative RT on metastasis suggests a likely immune effect at distal sites more than local ablative effect. Indeed, distant metastasis is dramatically increased with CD8-depletion (data not shown). Unexpectedly, the addition of chemotherapy (paclitaxel) actually increased the number of tumor colonies and exclusively erased the suppressive effect of ablative RT on metastasis (Fig. 3C ). To test whether the negating effect of chemotherapy (dacarbazine) was directly on CD8 + T cell priming, naïve CFSE labeled 2C cells were adoptively transferred into B16-SIY tumor bearing mice that received RT on day 0, chemotherapy on day 2 post transfer, and were then sacrificed on day 4 to determine the degree of T cell priming in the DLN and the spleen. Our results illustrate that the addition of chemotherapy to the RT group does indeed abolish priming of CD8 + T cells and chemotherapy given alone does not elicit CTL proliferation (Fig. 3D ). Therefore, it is possible that many types of chemotherapy regimens may forestall CTL generation, especially when followed by local RT, leading to the increased incidence of recurrent tumor.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Our study also raised concern about fractionated RT, another potentially immunosuppressive conventional treatment. Fractionated RT delivers low daily doses of radiation to the tumor over weeks, in contrast to ablative hypofractionated radiation which employs 1-5 larger doses usually administered in 1-7 days. To test the relative effectiveness of these treatment schemes in immune competent models, we designed two protocols delivering the same total RT dose: 5 Gy x4 over two weeks or single 20 Gy. Surprisingly, even though the 5 Gy x4 treated mice initially responded to RT, over time tumors relapsed in a manner analogous to the CD8 depleted 20 Gy RT condition (Fig. 3E) or with adoptive transfer of T cells alone (Fig. 3F) . These data suggest that the immune stimulating effects of RT are also applicable to human tumors and accordingly, convey the need to revisit conclusions based on models that utilized immunodeficient mice.
Local immunotherapy can amplify radiation-initiated immunity to eradicate disseminated metastasis
Our study opens the avenue for new strategies, such as RT and immunotherapy, to 
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in the RT + ad-LIGHT group (Fig. 4) . Impressively, most mice (86%) treated with RT and ad-LIGHT showed prolonged survival (> 100 days) while all mice treated with either radiation or ad-LIGHT died in < 60 days (data not shown). Together these data demonstrate that RT in combination with immunotherapy can better control metastasis than either single treatment.
Discussion
Recently, enabled by technological advances in targeting of radiotherapy, there has been an increased interest in utilizing 1-3 high doses of radiation in contrast to low dose fractionation.
Initially applied to arteriovenous malformations, benign brain tumors and brain metastasis (referred to as radiosurgery), there are now clinical trials applying this concept to extracranial targets. Recently, it has been suggested that high-dose single-fraction RT achieves better local control than would be predicted, implicating alternative mechanisms beyond direct killing of tumor cells 28 . It has been suggested that damage to the tumor-associated endothelium contributes to the superior local anti-tumor effect of high-dose radiation 29 . We have recently observed that stereotactic body radiation therapy (SBRT) effectively targets ablative doses of RT to isolated oligometastasis 17, 18 . Most patients with oligometastasis die in 6 months due to the lack of treatment and rapid progression of tumor. Our clinical data showed that better survival of patients with oligometastasis is closely associated with higher dose of RT: 1/6 (15%) of patients showed no significant differences from no treatment group while the radiation + T cell group showed significantly smaller tumor size (*p=0.018 at d60). Similar experiments were repeated at least two times (A-F). 
